Although companion diagnostics for PD-1, programmed death-ligand 1 (PD-L1) and CTLA-4 are actively used prior to initiating immunotherapy to confirm expression in tumor tissue samples, mutations in the HLA pathways may often be overlooked – which will impair or abolish productive anti-cancer directed cellular immune responses. Here, CTLA4 is linked to cancer.